Expanded Access Policy
Kinevant conducts clinical trials to assess the safety, efficacy, and other important scientific information about its investigational products. Regulatory agencies such as the U.S. Food and Drug Administration must review and approve investigational products before they can be made generally available to the public. Kinevant encourages patients to be aware of opportunities to participate in clinical trials. Clinical trials are the safest way for patients to access investigational products before regulatory approval.
Find a trial on clinicaltrials.gov (all sponsors, including Kinevant)
Sometimes called “compassionate use”, expanded access is a potential pathway for a patient with an immediately life-threatening condition or serious disease or condition to gain access to an investigational medical product for treatment outside of clinical trials when no comparable or satisfactory alternative therapies are available.
At this time Kinevant does not offer expanded access to its investigational products. These can only be accessed through participation in a clinical trial. Should Kinevant decide to offer access to an investigational product through expanded access in the future, this policy will be updated.
Contact Information
If you have any questions regarding Kinevant’s expanded access policy, please email us at medaffairs@kinevant.com.
Please be aware that Kinevant has entities in the United States and Switzerland, which are both involved in the execution of clinical trials and other actions related to an investigational product, such as expanded access. Therefore, please be aware that any personal data disclosed in your email will potentially be accessed and processed in the United States and/or Switzerland. Kinevant processes and transfers all data in line with applicable data protection laws.
Kinevant may revise this expanded access policy at any time.
Last updated: 9/24/2024